Home › Research › BPC-157 + TB-500 Blend
RESEARCH USE ONLY — This article describes compounds studied in laboratory and pre-clinical research. It is not intended for human or animal administration.

BPC-157 + TB-500 (Wolverine Stack)

Healing & Recovery Two-compound research pairing Status: Research Compounds

Studied for: the combination of BPC-157 and TB-500 is discussed in healing- and recovery-focused research contexts because the two peptides are reported to act through largely distinct, complementary pathways.

Distinct mechanisms, not a proven synergy. BPC-157 is associated with NO- and VEGF-related angiogenesis research, while TB-500 (the LKKTETQ fragment of Thymosin β4) is associated with actin dynamics and cell migration. Combined "synergy" is widely claimed in non-academic sources but is not established in controlled research.

Research-use only · largely pre-clinical · not FDA-approved.

The pairing of BPC-157 and TB-500 — colloquially nicknamed the "Wolverine Stack" in non-academic communities — is one of the most frequently discussed peptide combinations in healing and recovery research. This page summarizes what the published literature on each compound does, and does not, show, and explains why the two are often studied side by side. It does not describe a single combination product, an approved therapy, or any administration protocol. Both compounds have been studied almost entirely in in vitro and animal models, and neither is an approved drug.

Overview of the Combination

BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a portion of a human gastric protein; its preclinical literature centers on angiogenesis and connective-tissue repair models, largely from the Sikiric group.1,4 TB-500 is a synthetic heptapeptide reproducing the LKKTETQ actin-binding domain of Thymosin β4, studied for actin regulation and cell migration.13,14 Because the two are associated with different molecular pathways, they are frequently grouped together in recovery-focused research discussions — the rationale being that they may address different stages or aspects of tissue-repair models rather than duplicating the same effect.

"Stacking" the two is a community convention, not a research-validated protocol. No controlled study has established that the combination outperforms either compound alone.

Combined Mechanisms — what each contributes

The two peptides are characterized in the literature through largely non-overlapping pathways:

  • BPC-157 — angiogenesis & the NO system. Reported to upregulate VEGF-related signalling and interact with the nitric oxide (NO) pathway in vascular and tissue-repair models.4,6,8
  • BPC-157 — connective-tissue repair. Studied in tendon, ligament, and gastrointestinal healing models, including effects on cell survival and migration in tendon research.5,2
  • TB-500 — actin sequestration. The LKKTETQ domain binds monomeric (G-)actin and is described as a regulator of the actin cytoskeleton, influencing cell shape and migration.13,14
  • TB-500 — cell migration & angiogenesis. Through actin dynamics, Thymosin β4 has been reported to promote directed cell migration and pro-angiogenic activity in wound-repair models.15,16

The frequently cited rationale for studying them together is that BPC-157's vascular/angiogenic associations and TB-500's actin/migration associations describe different contributors to tissue-repair models. This complementarity is a hypothesis drawn from separate single-compound studies, not a demonstrated combined effect.4,16

These mechanisms are characterized predominantly in laboratory and animal studies — much of the TB-500 evidence concerns full-length Thymosin β4 rather than the fragment specifically.

Research Applications — what has been studied

The following are areas of published laboratory and pre-clinical investigation for the individual compounds, not approved uses, treatment indications, or validated combination outcomes:

  • Tendon & ligament models — BPC-157 has the stronger replication base here (e.g., Achilles models).5
  • Soft-tissue & dermal repair — both compounds appear in wound-healing and regeneration models.2,15
  • Angiogenesis — NO/VEGF-pathway work for BPC-157; actin-linked pro-angiogenic activity for Thymosin β4.6,16
  • Gastrointestinal models — a BPC-157-specific area (fistula and IBD-type models).7
  • Cell migration & cytoprotection — actin-dependent migration for TB-500; cytoprotection/stress-response framing for BPC-157.9,20

Human data. Controlled human trials are lacking for both compounds; the combined "Wolverine Stack" has no published controlled human trial data at all.21

What the Literature Does Not Establish

An honest read of the combination requires naming the gaps:

  • No randomized, placebo-controlled human trials of the BPC-157 + TB-500 combination have been published.
  • Claims that the two act "synergistically" are not supported by controlled combination studies — the evidence is two separate single-compound literatures.
  • Most TB-500 evidence describes full-length Thymosin β4; fragment-specific data is a limited subset.
  • Human pharmacokinetics, long-term safety, and any combined-use safety profile are not established. Neither compound is FDA-approved for any use.

Why These Two Are Studied Together

Within healing-and-recovery research discussion, BPC-157 and TB-500 are paired because their proposed mechanisms are mechanistically distinct — NO/VEGF-driven angiogenesis versus actin-driven cell migration — so researchers and writers frame them as potentially addressing different aspects of a repair model. Related compounds discussed in the same context include GHK-Cu and Thymosin Alpha-1. As with all such pairings, co-administration "synergy" is a popular claim that remains unproven in controlled research; treat it with caution.

Plan and compare on the research tools

Model reconstitution and supply for individual research compounds, or browse documented research stacks — for laboratory reference only, no administration guidance.

Open the Research Calculator Browse the Protocol Library

Citations

All references are peer-reviewed and link to their PubMed records. Verify each independently. Citations 1–12 concern BPC-157; 13–21 concern TB-500 / Thymosin β4, much of which describes the full-length protein rather than the LKKTETQ fragment specifically.

  1. Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals (Basel). 2025. PMID 40005999
  2. Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. PMID 34267654
  3. Lee E, et al. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. PMID 34324435
  4. Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors: GI-Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018. PMID 29998800
  5. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID 21030672
  6. Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014. PMID 23782145
  7. Sikiric P, et al. Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des. 2020. PMID 32329684
  8. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157–NO-system relation. Curr Pharm Des. 2014. PMID 23755725
  9. Sikiric P, et al. BPC 157, Robert's Cytoprotection/Organoprotection, and Selye's Stress-Coping Response. Gut Liver. 2020. PMID 31158953
  10. Vukojevic J, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022. PMID 34380875
  11. Park JM, et al. BPC 157 Rescued NSAID-Cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des. 2020. PMID 32445447
  12. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut and Gut-Brain Axis Function. Pharmaceuticals (Basel). 2023. PMID 37242459
  13. Hannappel E. β-Thymosins. Ann N Y Acad Sci. 2007. PMID 17468232
  14. Huff T, et al. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001. PMID 11311852
  15. Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003. PMID 12581423
  16. Philp D, Kleinman HK. Animal studies with thymosin β, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010. PMID 20536453
  17. Bjørklund G, et al. Thymosin β4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury. Curr Med Chem. 2020. PMID 31333080
  18. Renga G, et al. Thymosin β4 limits inflammation through autophagy. Expert Opin Biol Ther. 2018. PMID 30063848
  19. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018. PMID 30063853
  20. Wirsching HG, et al. Thymosin β4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain. 2014. PMID 24355709
  21. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. PMID 22074294

Where to Source for Research

The vendors below supply research-grade BPC-157 and TB-500. Affiliate disclosure: PMP earns commission on referred orders at no additional cost to the buyer.

AminoClub · code ROCN
Use code ROCN — 20% off first order, 10% recurring
Apollo Peptide Sciences
Direct affiliate link — no code needed
Licensed Peptides · code Affiliate5
Use code Affiliate5 for 5% off

Frequently Asked Questions

Is the BPC-157 + TB-500 "Wolverine Stack" FDA-approved?

No. Neither BPC-157 nor TB-500 is approved by the U.S. Food and Drug Administration for any clinical application, and no combination product is approved. Both remain classified as research compounds supplied for laboratory work only.

Why are BPC-157 and TB-500 studied together?

They are associated with largely distinct, complementary pathways in the published literature — BPC-157 with NO- and VEGF-related angiogenesis research, and TB-500 with actin dynamics and cell migration. That mechanistic difference is why writers and researchers discuss them side by side in healing-and-recovery contexts.

Is the synergy between BPC-157 and TB-500 proven?

No. Combined "synergy" is widely claimed in non-academic sources but has not been established in controlled research. The evidence base is two separate single-compound literatures, not controlled studies of the combination.

What does the research literature show about the combination?

There are no published controlled human trials of the combination. The available evidence is pre-clinical and animal-model work on each compound individually, summarized in the body and citations of this article; much of the TB-500 literature concerns full-length Thymosin beta 4 rather than the fragment specifically.

Where can I source BPC-157 and TB-500 for research purposes?

See the Where to Source section above for vendors that supply research-grade BPC-157 and TB-500. Listed vendors are affiliate partners of Peptide Manager Pro; we earn a small commission on referred orders at no additional cost to the buyer.

Are BPC-157 and TB-500 safe for human or animal use?

Both compounds are sold for in vitro and laboratory research only. They are not intended for human or veterinary administration, and no safety determination for such use — individually or combined — has been established by the U.S. Food and Drug Administration or any equivalent regulatory body.